Nephros (NEPH) Earnings Date & Reports

Key Takeaways

• Nephros reported third quarter 2026 net revenue of approximately $5.6 million, an 18% increase from $4.8 million in the prior-year period.
• Diluted earnings per share (EPS) came in at $0.05, up from $0.03 a year ago and ahead of the roughly $0.03 consensus estimate.
• Core programmatic revenue grew about 8% year over year, while the active customer base reached a record 1,766 sites.
• Gross margin eased to roughly 58% from 61%, reflecting tariffs, foreign exchange, freight costs, and a higher mix of lower-margin service revenue.
• Net income rose to approximately $0.5 million from $0.3 million, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) increased to about $0.6 million.
• The company remained debt-free with roughly $4.5 million in cash and cash equivalents as of September 30, 2026.
• For more detail on Nephros, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover automated market strategies on the Trending AI Robots page.

Earnings Context and Why It Matters

Nephros, Inc. is a commercial-stage water technology company that develops filtration solutions for medical and commercial markets, including ultrafiltration products used in dialysis centers, hospitals, and hospitality settings. Its quarterly results offer investors a direct read on demand for water-safety and infection-control products, a segment that has expanded beyond healthcare into commercial and industrial applications. The third quarter report matters because it tests whether the company can sustain its double-digit revenue momentum while managing margin pressure from tariffs, currency swings, and a growing but lower-margin services business. With the company newly profitable and added to the Russell Microcap Index in 2026, each report also serves as a checkpoint on its transition toward a broader products, services, and education model.

Reported Results

For the three months ended September 30, 2026, Nephros reported net revenue of approximately $5.6 million, an 18% increase from $4.8 million in the same period of 2025. Product revenue rose to about $5.4 million, while service, royalty, and other revenue reached roughly $0.2 million. Core programmatic revenue increased approximately 8% year over year, and the company added to its active customer base, which reached a record 1,766 sites.

Net income for the quarter was approximately $0.5 million, or $0.05 per diluted share, compared with about $0.3 million, or $0.03 per diluted share, a year earlier. Adjusted EBITDA increased to approximately $0.6 million from about $0.4 million. Gross margin came in at roughly 58%, down from 61% in the prior-year quarter, as higher inventory, shipping, and tariff costs combined with faster growth in lower-margin service revenue.

For the nine months ended September 30, 2026, net revenue grew 20% to approximately $16.9 million, core programmatic revenue rose 19%, and net income increased to about $1.8 million. The company ended the quarter with roughly $4.5 million in cash and no debt.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking small-cap names like Nephros, it can surface comparable opportunities and technical setups across the water technology and medical-device industries. Explore the AI Screener to refine your research workflow.

Market Reaction and Investor Sentiment

Shares of Nephros have faced sustained pressure over the trailing year even as the company has posted consistent revenue and profit growth. As of the third quarter report, the stock traded well below its 52-week high, with double-digit declines over the trailing three- and twelve-month periods. The market appears to be weighing near-term margin compression and the company's relatively small float against its improving profitability and debt-free balance sheet. Investor sentiment heading into the report focused on the durability of programmatic reorders and whether gross margins could stabilize despite persistent tariff and currency headwinds. The earnings beat on the bottom line provided a positive data point, but the modest gross-margin decline and the evolving revenue mix toward lower-margin services remain central considerations for the stock's next leg.

Forward Outlook and Key Factors to Monitor

Nephros enters the final stretch of 2026 with momentum in recurring, programmatic revenue and an expanding installed base. Management has framed the business around three complementary capabilities — products, services, and education — with healthcare remaining the core market while commercial and industrial applications grow. Investors should watch whether the record active-site count translates into sustained replacement and reorder demand, which underpins the recurring revenue model.

Margins remain the key swing factor. Tariff costs, a weaker U.S. dollar relative to the euro, and elevated shipping expenses continue to pressure gross margin, while the rapid growth of service and commercial product revenue — both lower-margin than the core infection-control business — dilutes the blended figure. Monitoring whether gross margin stabilizes near current levels will be important for assessing profitability trends.

Other catalysts to track include the adoption of newer product lines addressing PFAS (per- and polyfluoroalkyl substances), microplastics, and sterile processing, as well as expansion efforts in the Greater New York market and Puerto Rico. The company's cash position and debt-free balance sheet provide flexibility to fund these initiatives. As always, results should be evaluated against the company's own disclosures rather than assumed calendar-quarter patterns, given its standard fiscal year ending December 31.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations